🕒 Last update: loading…19/11/2026

Stock Medtronic Plc 2M6.DE

Medtronic Plc — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met. Data as of 01/11/2026.

  • ❌ Price trend failed
  • ⚠️ Mixed growth
  • ❌ Debt failed
  • ✅ P/E passed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: 28.31%

Price change 2019 → 2020: -6.67%

Price change 2020 → 2021: -1.95%

Price change 2021 → 2022: -21.34%

Price change 2022 → 2023: 2.88%

Price change 2023 → 2024: 3.19%

Price change 2024 → 2025: 6.75%

Price change 2025 → 2026: 5.96%

Price change 2026 (year to date): 6.89%

Financial growth

Revenue CAGR (8 years): 2.52%

Earnings CAGR (8 years): 0.51%

Growth status: positive trend (>1%/yr) in revenue OR earnings, but not both.

Debt

Debt-to-equity ratio: 0.57

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: 18.35

P/E < 25.0 (maximum threshold).

Correction (6 months)

Current correction: 0.00% from the high over 6 months.

Insufficient correction (< 10.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…
03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Medtronic Plc over the latest fiscal years.

Revenue
36.4 bn USD
fiscal year 2026
Net income
4.8 bn USD
fiscal year 2026
Net margin
13.2 %
fiscal year 2026
Average annual growth
+3.8 %
Revenue growth over 5 years
Average annual growth
+2.3 %
Revenue growth over 10 years
Market cap
132 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
202130.1 bn3.6 bn12.0 %n/a
202231.7 bn5.0 bn15.9 %+5.2 %
202331.2 bn3.8 bn12.0 %-1.4 %
202432.4 bn3.7 bn11.4 %+3.6 %
202533.5 bn4.7 bn13.9 %+3.6 %
202636.4 bn4.8 bn13.2 %+8.4 %

Amounts converted to USD. Source: published annual accounts, collected on 19/11/2026.

+

Valuation and competitors

Medtronic Plc compared with its sector on the same exchange and with its main competitors.

Company P/E
18.6
42.8 % below the sector
Sector median P/E
32.5
healthcare, Xetra
Sector over 10 years
26.9
10-year median, range 20.7 to 68.4

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 16/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering Medtronic Plc publish: ratings, price targets and earnings forecasts.

Majority rating
buy
51 analysts

Breakdown of ratings

strong buy 1buy 30hold 20sell 0strong sell 0

Price targets: published for companies listed in the United States only.

Analyst forecasts

Fiscal yearRevenueNet incomeExpected EPS (range)P/E on this EPSAnalysts
202636.1 bn7.2 bn5.52 (5.49 / 5.62)n/a18
202739.0 bn7.7 bn5.98 (5.96 / 6.00)n/a18
202840.3 bn8.2 bn6.39 (6.28 / 6.55)n/a17

Amounts in USD, the reporting currency.

Track record against expectations: reported EPS above consensus 12 times over the last 12 releases.

Rating changes (12 months)

DateFirmBeforeAfter
12/10/2026BTIGBuyBuy
30/09/2026TD CowenBuyBuy
03/09/2026UBSBuyBuy
02/09/2026RBC CapitalOutperformOutperform
02/09/2026Wells FargoOverweightOverweight

Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee. Company data collected from its MDT listing (same ISIN).

+

Dividends and earnings

Medtronic Plc: dividend history, last distributions, stock splits and earnings releases.

Frequency
quarterly
Last dividend
0.633
ex-dividend on 25/09/2026
Last 12 months
2.50
number of payments: 4
Years of increases
0
consecutive
Years of payments
18
uninterrupted
00.691.382.062.752008 : 1.3120082009 : 1.052010 : 0.86020102011 : 0.9352012 : 1.2620122013 : 0.2602014 : 1.2020142015 : 1.452016 : 1.6720162017 : 1.692018 : 1.9620182019 : 2.122020 : 2.2820202021 : 2.472022 : 2.6720222023 : 2.752024 : 2.7220242025 : 2.422026 : 1.892026

Annual dividend per share (), adjusted for splits. Light bar: current year, incomplete. Red bar: lower than the previous year.

Latest ex-dividend dates

Ex-dividendAmountPayment
25/09/20260.63316/10/2026
26/06/20260.63217/07/2026
27/03/20260.62517/04/2026
29/12/20250.60616/01/2026
26/09/20250.60617/10/2025
27/06/20250.60611/07/2025
28/03/20250.59811/04/2025
27/12/20240.67210/01/2025

Earnings releases

Next release: 24/11/2026. Expected EPS: 1.20.

DatePublished EPSExpected EPSSurprise
01/09/20261.261.21+4.1 %
03/06/20261.321.31+0.8 %
17/02/20261.151.13+1.8 %
18/11/20251.181.14+3.5 %
19/08/20251.101.08+1.9 %
21/05/20251.431.40+2.1 %

Factual data: ex-dividend history and earnings calendar, as of 18/11/2026. A past dividend does not guarantee the next one.

+

PEA and practical information

PEA eligibility
likely
head office in the EU or EEA, listed on a European exchange
Listing exchange
Xetra
IPO: 28/12/2007
ISIN code
IE00BTN1Y115
Workforce
95,000
full-time employees
Chief executive
Geoffrey Straub Martha
Next earnings
24/11/2026

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Medtronic Plc

What is the revenue of Medtronic Plc?

36.4 bn USD for fiscal year 2026, with net income of 4.8 bn USD (net margin 13.2 %).

Does Medtronic Plc pay a dividend?

Yes. Latest dividend: 0.633 per share, ex-dividend on 25/09/2026. Over 12 months: 2.50.

When does Medtronic Plc report its next earnings?

The next release is expected on 24/11/2026. EPS expected by analysts: 1.33.

What do analysts say about Medtronic Plc?

Out of 51 analysts: 31 buy or strong buy, 20 hold, 0 sell or strong sell.

What is the P/E ratio of Medtronic Plc?

Trailing 12-month P/E of 18.6, against 32.5 for the sector median on the same exchange (10-year median: 26.9).

Is Medtronic Plc stock eligible for the French PEA?

Likely: the company is headquartered in the European Union or the European Economic Area (ISIN IE00BTN1Y115) and the stock is listed on a European exchange. The institution holding the PEA confirms eligibility.

How many employees does Medtronic Plc have?

95,000 full-time employees according to the latest published profile.

Who runs Medtronic Plc?

Geoffrey Straub Martha is the company's chief executive.